GlassScriptPhysician profile
Nicholas P Willis
NPI 1629292883
$14,649.10
in general payments reported to CMS, 2019-2025
41 companies · $2,822 in 2025
The $2,822 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $1,144 · 2021: $1,261 · 2022: $3,186 · 2023: $3,463 · 2024: $1,137 · 2025: $2,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,651 · Travel and Lodging: $2,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,651.26 |
| Travel and Lodging | $2,771.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,611.58 | 2022-2025 | Selectsecure, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Penumbra, INC. | $2,156.38 | 2023 | Indigo System |
| Amgen INC. | $1,347.23 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,180.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $559.09 | 2021-2025 | Verquvo, Belsomra |
| Pfizer INC. | $548.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $508.79 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $468.21 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Abbott Laboratories | $432.36 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.94 | 2020-2025 | Lifevest |
| Medtronic Vascular, INC. | $306.62 | 2019-2020 | |
| Abiomed | $251.89 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $241.99 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $220.41 | 2019-2024 | Farxiga, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $191.87 | 2019-2025 | Camzyos, Eliquis |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $188.27 | 2019-2022 | |
| Novo Nordisk INC | $174.27 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $173.45 | 2025 | Pascal |
| Philips North America LLC | $149.97 | 2020-2025 | Ecc Solutions, (Ck7) Extended Holter, (Ck4) Mcot |
| Shockwave Medical, INC | $147.57 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $139.10 | 2020-2023 | Nexletol |
| Mallinckrodt Enterprises LLC | $130.72 | 2019 | |
| Boston Scientific Corporation | $123.16 | 2021-2023 | Watchman |
| Lexicon Pharmaceuticals, INC. | $123.02 | 2023-2024 | Inpefa |
| Cardiovascular Systems INC. | $108.21 | 2019-2022 | |
| Baxter Healthcare | $102.98 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $101.95 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.20 | 2019 | |
| Alnylam Pharmaceuticals INC. | $77.46 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.46 | 2019-2023 | Jardiance |
| Irhythm Technologies, INC. | $72.39 | 2019-2024 | Zio Xt Patch, Zio At Patch |
| Mallinckrodt Hospital Products INC. | $69.83 | 2020-2022 | |
| Cvrx, INC. | $51.21 | 2024-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $36.88 | 2025 | |
| Coloplast Corp | $31.75 | 2025 | |
| Kestra Medical Technology Services, INC. | $24.61 | 2025 | Assure Wcd |
| Elutia, INC. | $23.01 | 2021 | |
| Cardiva Medical, INC. | $22.22 | 2025 | Cardiva Vascade 6/7f Vcs |
| Genentech USA, INC. | $20.32 | 2024 | Tecentriq, Phesgo |
| Bridgebio Pharma, INC. | $17.31 | 2025 | Attruby |
| Sunovion Pharmaceuticals INC. | $16.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.